JW Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- JW Therapeutics's estimated annual revenue is currently $20.3M per year.
- JW Therapeutics's estimated revenue per employee is $155,000
Employee Data
- JW Therapeutics has 131 Employees.
- JW Therapeutics grew their employee count by -5% last year.
JW Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is JW Therapeutics?
JW Therapeutics is an innovative biotech company focusing on the latest clinical cell therapy technology. It is commited to the development, transformation and promotion of breakthrough cell-based immunotherapies to save the lives of cancer patients, improve their quality of life and bring new hope. JW Therapeutics was co-founded by WuXi AppTec, Juno Therapeutics in February 2016.
keywords:N/A
N/A
Total Funding
131
Number of Employees
$20.3M
Revenue (est)
-5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
JW Therapeutics News
NEW YORK JW Therapeutics said on Wednesday that China's National Medical Products Administration (NMPA) has cleared an investigational new...
JW Therapeutics (HKEx: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing...
SHANGHAI, March 31, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on...
Other Companies in 上海
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $20.8M | 134 | -15% | N/A |
#2 | $49.5M | 150 | -6% | N/A |
#3 | $33.8M | 152 | -3% | N/A |
#4 | $61.7M | 170 | -1% | N/A |
#5 | $43.2M | 215 | 0% | N/A |